News
AIM
0.1901
-6.49%
-0.0132
AIM ImmunoTech CEO issues letter to stockholders
TipRanks · 4d ago
Weekly Report: what happened at AIM last week (0914-0918)?
Weekly Report · 5d ago
AIM ImmunoTech Executes Debt-Reducing Equity Exchange Agreements
TipRanks · 09/14 21:39
Weekly Report: what happened at AIM last week (0907-0911)?
Weekly Report · 09/14 09:53
AIM ImmunoTech Reduces Debt via Equity Exchange Agreements
TipRanks · 09/10 21:01
Weekly Report: what happened at AIM last week (0831-0904)?
Weekly Report · 09/07 09:49
AIM ImmunoTech Extinguishes Debt Through Equity Exchanges
TipRanks · 09/04 21:40
AIM ImmunoTech Secures Europe, U.K. Patent Protection For Ampligen In Long COVID; Shares Jump
NASDAQ · 09/03 07:50
AI-Media Puts Multilingual AI at the Heart of the Broadcast Workflow at IBC2026
Barchart · 09/03 05:00
AIM ImmunoTech Significantly Expands Ampligen® Global Patent Estate with Long COVID Protection Across Europe and the United Kingdom Through 2041
Barchart · 09/02 07:43
12 Health Care Stocks Moving In Monday's Intraday Session
Benzinga · 08/31 17:06
AIM ImmunoTech granted patent for Ampligen
TipRanks · 08/31 13:00
Weekly Report: what happened at AIM last week (0824-0828)?
Weekly Report · 08/31 09:54
Why Now On-Demand Conference Spotlights Nine Emerging Biotech And Healthcare Stories
NASDAQ · 08/29 10:34
JTC Team Releases Virtual Investor "Why Now" On-Demand Conference Featuring Nine Public Company CEOs
Barchart · 08/27 08:01
AIM ImmunoTech Participates in the Virtual Investor ‘Why Now’ On-Demand Conference
Barchart · 08/27 08:01
Analysts Are Bullish on Top Healthcare Stocks: AIM ImmunoTech (AIM), Niagen Bioscience (NAGE)
TipRanks · 08/24 11:10
Weekly Report: what happened at AIM last week (0817-0821)?
Weekly Report · 08/24 09:54
AIM ImmunoTech Is Maintained at Buy by Ascendiant Capital
Dow Jones · 08/20 10:12
AIM ImmunoTech Price Target Cut to $7.00/Share From $9.00 by Ascendiant Capital
Dow Jones · 08/20 10:12
More
Webull provides a variety of real-time AIM stock news. You can receive the latest news about Aim Immunotech through multiple platforms. This information may help you make smarter investment decisions.
About AIM
AIM ImmunoTech Inc. is an immuno-pharma company. The Company is focused on the research and development of therapeutics to treat multiple types of cancers, immune disorders and viral diseases, including COVID-19. The Company’s flagship products are Ampligen (rintatolimod) and Alferon N Injection (Interferon alfa). Ampligen is a double-stranded RNA (dsRNA) and highly selective TLR3 agonist immuno-modulator, which is being developed for globally important cancers, viral diseases and disorders of the immune system. Ampligen is approved for commercial sale in the Argentine Republic for the treatment of severe chronic fatigue syndrome (CFS). Alferon N Injection is an injectable formulation of natural alpha interferon, which is approved for sale in the United States and Argentina for the intralesional treatment of refractory or recurring external genital warts in patients 18 years of age or older.